Endpoints News

RA Capital backs intranasal viral prophylactic startup		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M Tue W Th F

23 June, 2026

A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.

SPOTLIGHT

No investors. A 50/50 split everyone warned us against. How Endpoints survived its first decade — and ended up at the FT

news

Exelixis' TKI falls short in colorectal cancer subgroup as FDA reviews approval in all-comers

Exclusive: Brent Saunders' latest dermatology bet gets $20M for skin longevity

Exclusive: RA Capital backs intranasal viral prophylactic with $34M and a plan for Phase 2b

Exclusive: Flagship's Abiologics uses AI to build mirror-image proteins for new drugs

Jul 30

1:00 pm ET

Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights

sponsored by GUARDANT

Biopharma has metabolized the tariff chaos, but the ground keeps shifting under manufacturing and supply chain teams. Hear directly from the experts on what’s changed, what’s working, and what to watch. Join us.

PHARMA

HHS rolls out sweeping clinical trial reforms to counter China, RFK Jr. says

•

Post-Hoc Live: Are the China hawks winning?

After 'redesign,' WuXi Biologics sets new timeline for Massachusetts factory completion

Sanofi R&D leader Houman Ashrafian to depart, Paulo Fontoura to take the reins

News Briefing

Lilly allies with BioArctic; Antengene and Insilico sign deals

in case you missed it

AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates

Merck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win

MapLight to discuss future of autism drug with FDA despite Phase 2 disappointment

Definium reports Phase 3 hit for LSD drug in severe form of depression

Bionyra's $165M launch: A Sanofi alum, I&I candidates from China, one big catch-up

Nura Bio gets $73.8M to advance SARM1 inhibitors for neurodegeneration

Billionaire French pharma heir leaves riches to mystery charity

Endpoints News turned 10 years old this week. Founders Arsalan Arif and John Carroll have a story here looking back to where it all started and how the newsroom has evolved.